

# OUTCOMES MATTER

THE POWER OF PROSPECTIVE OUTCOMES

NEARLY

**50,000**

BREAST CANCER PATIENTS  
ACROSS 6 COUNTRIES

## TAILORx Study<sup>1</sup>

One of the largest-ever adjuvant breast cancer trials indentifying which patients can *effectively* use hormone therapy alone, avoiding the negative effects of chemotherapy.



**99%**  
of women

with a low Oncotype DX<sup>®</sup> breast cancer Recurrence Score<sup>®</sup> (RS) result <11 were free of breast cancer recurrence after 5 years of hormone therapy alone.

## SEER-NCI Study<sup>2</sup>

Outcomes data in >44,500 Oncotype DX patients reveal:

At 5 years, patients with RS <18 had excellent Breast Cancer Survival;


**BCSM**  
(breast cancer specific mortality)

**<0.5% for node [-]**

**1% for node [+]**

**Women  $\geq 70$  years old** were **3x less likely** than younger women to be tested and had *worse* breast cancer survival

Significant geographic inequalities in Oncotype DX testing.



**ASK YOUR DOCTOR ABOUT ACCESS TO ONCOTYPE DX WHERE YOU LIVE**

1. N Engl J Med. 2015 Nov 19;373(21):2005-14

2. Shak, S. Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database. Poster session presented at: San Antonio Breast Cancer Symposium; December 2015; San Antonio, TX.